Epizyme Share Holder Equity 2012-2022 | EPZM

Epizyme share holder equity from 2012 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Epizyme Annual Share Holder Equity
(Millions of US $)
2021 $-21
2020 $185
2019 $331
2018 $233
2017 $235
2016 $202
2015 $170
2014 $160
2013 $104
2012 $-51
2011 $-51
Epizyme Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $11
2021-12-31 $-21
2021-09-30 $15
2021-06-30 $68
2021-03-31 $123
2020-12-31 $185
2020-09-30 $244
2020-06-30 $293
2020-03-31 $340
2019-12-31 $331
2019-09-30 $294
2019-06-30 $326
2019-03-31 $368
2018-12-31 $233
2018-09-30 $172
2018-06-30 $206
2018-03-31 $231
2017-12-31 $235
2017-09-30 $268
2017-06-30 $150
2017-03-31 $175
2016-12-31 $202
2016-09-30 $234
2016-06-30 $255
2016-03-31 $279
2015-12-31 $170
2015-09-30 $190
2015-06-30 $209
2015-03-31 $218
2014-12-31 $160
2014-09-30 $173
2014-06-30 $190
2014-03-31 $201
2013-12-31 $104
2013-09-30 $87
2013-06-30 $96
2013-03-31 $0
2012-12-31
2012-09-30 $0
2012-06-30 $0
2011-12-31 $-51
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.244B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00